EP1539246A4 - Verabreichung in die zentralen luftwege zur systemischen abgabe von therapeutika - Google Patents

Verabreichung in die zentralen luftwege zur systemischen abgabe von therapeutika

Info

Publication number
EP1539246A4
EP1539246A4 EP03762973A EP03762973A EP1539246A4 EP 1539246 A4 EP1539246 A4 EP 1539246A4 EP 03762973 A EP03762973 A EP 03762973A EP 03762973 A EP03762973 A EP 03762973A EP 1539246 A4 EP1539246 A4 EP 1539246A4
Authority
EP
European Patent Office
Prior art keywords
introduction
therapeutic agents
systemic administration
central airways
airways
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03762973A
Other languages
English (en)
French (fr)
Other versions
EP1539246A2 (de
Inventor
Richard S Blumberg
Wayne I Lencer
Neil E Simister
Alan J Bitonti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Bioverativ Therapeutics Inc
Original Assignee
Brigham and Womens Hospital Inc
Boston Childrens Hospital
Brandeis University
Syntonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/021335 external-priority patent/WO2003077834A2/en
Application filed by Brigham and Womens Hospital Inc, Boston Childrens Hospital, Brandeis University, Syntonix Pharmaceuticals Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP1539246A2 publication Critical patent/EP1539246A2/de
Publication of EP1539246A4 publication Critical patent/EP1539246A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP03762973A 2002-07-03 2003-05-09 Verabreichung in die zentralen luftwege zur systemischen abgabe von therapeutika Withdrawn EP1539246A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOPCT/US02/21335 2002-07-03
PCT/US2002/021335 WO2003077834A2 (en) 2002-03-15 2002-07-03 Central airway administration for systemic delivery of therapeutics
PCT/US2003/014428 WO2004004798A2 (en) 2002-07-03 2003-05-09 Central airway administration for systemic delivery of therapeutics

Publications (2)

Publication Number Publication Date
EP1539246A2 EP1539246A2 (de) 2005-06-15
EP1539246A4 true EP1539246A4 (de) 2007-05-16

Family

ID=30113575

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03762973A Withdrawn EP1539246A4 (de) 2002-07-03 2003-05-09 Verabreichung in die zentralen luftwege zur systemischen abgabe von therapeutika

Country Status (5)

Country Link
EP (1) EP1539246A4 (de)
JP (1) JP2006513139A (de)
AU (1) AU2003232081B2 (de)
CA (1) CA2491129A1 (de)
WO (1) WO2004004798A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2333598T5 (es) 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
BRPI0507174A (pt) 2004-01-28 2008-04-01 Syntonix Pharmaceuticals Inc proteìnas de fusão hormÈnio-fc (fsh-fc) heterodiméricas estimuladoras de folìculo para o tratamento da infertilidade
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
EP3342782B1 (de) 2004-07-15 2022-08-17 Xencor, Inc. Optimierte fc-varianten
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2004695A2 (de) 2005-07-08 2008-12-24 Xencor, Inc. Optimierte anti-ep-cam-antikörper
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
PL2383297T3 (pl) 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2660795C (en) 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
AU2008260498B2 (en) 2007-05-30 2012-11-29 Xencor, Inc. Methods and compositions for inhibiting CD32b expressing cells
CA2693771A1 (en) * 2007-07-13 2009-01-22 Abbott Biotechnology Ltd. Methods and compositions for pulmonary administration of a tnf.alpha. inhibitor
CA2720628A1 (en) 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins having mutated immunoglobulin hinge region
AU2008314697B2 (en) * 2007-10-22 2013-08-29 Merck Serono S.A. Single IFN-beta fused to a mutated lgG Fc fragment
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
JP5785493B2 (ja) 2008-09-17 2015-09-30 ゼンコア インコーポレイテッド ＩｇＥ媒介性疾患を治療するための新規組成物および方法
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
CN102492039B (zh) * 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
RU2729546C2 (ru) 2014-04-03 2020-08-07 Цсл Беринг Аг Распыление иммуноглобулина
AU2015292326A1 (en) 2014-07-24 2017-02-23 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
JP2019503341A (ja) * 2015-11-16 2019-02-07 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達
PL3468997T3 (pl) 2016-06-08 2024-12-16 Xencor, Inc. Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
EP4392455A4 (de) 2021-08-25 2025-08-20 Ibio Inc Anti-cd-25 antikörper

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004054A1 (en) * 1989-09-19 1991-04-04 Millar Ann Brigid Treatment of ards
WO1991016038A1 (en) * 1990-04-13 1991-10-31 Toray Industries, Inc. Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof
WO1996022024A1 (en) * 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002043660A2 (en) * 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002100387A1 (en) * 2001-06-11 2002-12-19 A+ Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA25590A1 (fr) * 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001074397A1 (fr) * 2000-03-31 2001-10-11 Kirin Beer Kabushiki Kaisha Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004054A1 (en) * 1989-09-19 1991-04-04 Millar Ann Brigid Treatment of ards
WO1991016038A1 (en) * 1990-04-13 1991-10-31 Toray Industries, Inc. Pharmaceutical aerosol formulation of solid polypeptide microparticles and method for the preparation thereof
WO1996022024A1 (en) * 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO2001049321A1 (en) * 1999-12-31 2001-07-12 Tobinick Edward L Tnf inhibitors for the treatment of neurological, retinal and muscular disorders
WO2001059142A1 (en) * 2000-02-09 2001-08-16 Medimmune, Inc. Antibody gene therapy with adeno-associated viral vectors
WO2002043660A2 (en) * 2000-11-28 2002-06-06 Mediummune, Inc Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
WO2002100387A1 (en) * 2001-06-11 2002-12-19 A+ Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
US20030235536A1 (en) * 2002-03-15 2003-12-25 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics

Also Published As

Publication number Publication date
JP2006513139A (ja) 2006-04-20
WO2004004798A2 (en) 2004-01-15
WO2004004798A3 (en) 2004-10-14
EP1539246A2 (de) 2005-06-15
AU2003232081A1 (en) 2004-01-23
AU2003232081B2 (en) 2009-02-05
CA2491129A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
ITMI20000312A0 (it) Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva
EP1487992A4 (de) Verabreichung über die zentralen luftwege für die systemische zuführung von therapeutika
EP1646276A4 (de) Zerstäuber zur erzeugung eines arzneimittels in aerosolform
NO2020019I1 (no) Maraviroc eventuelt i form av et farmasøytisk akseptabelt salt
EP1191933A4 (de) Nasale verabreichung von apomorphin
FR17C1027I2 (fr) Liposomes utiles pour l'administration de medicaments
MA27107A1 (fr) Formulations aerosoles pour l'administration pulmonaire de medicaments visant a produire un effet systemique.
EP1585504A4 (de) Proteinstabilisierte liposomale formulierungen pharmazeutischer wirkstoffe
FR2808685B1 (fr) Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
EP1337249A4 (de) Zusammensetzungen und verfahren zur verabreichung von pharmakologisch aktiven verbindungen
FR2806918B1 (fr) Catheter pour l'administration specifique d'un medicament
IL162294A0 (en) Formulation & dosage form for the controlled delivery of therapeutic agents
EP1807146A4 (de) Zusammensetzung zur verbesserung der effizienz der arzneiabgabe
EP1165597A4 (de) Bifunktionale moleküle zur verabreichung therapeutisch wirksamer stoffe
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
DZ3246A1 (fr) Dérivé heterocyclo-alkylsulfonyle pyrazole en tant qu'agents anti-inflammatoires/analgesiques
NO20014738D0 (no) Tolperisonholdig farmasöytisk preparat for oral administrering
EP1602366A4 (de) Pflastermaterial für ionische medizin-verabreichung
EP1293131A4 (de) Mittel zur rachenbehandlung
EP1406493A4 (de) Verabreichung von mitteln über den pept-2-transporter
EP1667528A4 (de) Hippophae- rhamnoides- zusammensetzungen für die krebstherapie
ITMI20020773A0 (it) Farmaci per il trattamento dell'artrite
EE200300501A (et) Ninna manustatavad imidasotriasinooni sisaldavad kompositsioonid
FI20000780L (fi) Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
ITMI20001051A0 (it) Formulazioni contenenti un farmaco glucocorticosteroide per il trattamento di patologie broncopolmonari

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070417

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20070411BHEP

Ipc: A61K 38/21 20060101ALI20070411BHEP

Ipc: A61K 38/23 20060101ALI20070411BHEP

Ipc: A61K 48/00 20060101AFI20050209BHEP

17Q First examination report despatched

Effective date: 20120125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120605